Artrya Signs First SAPPHIRE Commercial Deal, Delays Coronary Flow Filing
Closing price · 2026-10-26: $2.46 · +0.41%
Artrya says Huntsville Hospital Health System, its largest customer to date, has signed a five-year commercial agreement, marking the first SAPPHIRE study participant to convert to a customer; the deal includes a minimum commitment of about US$500,000. The company also reported materially higher Salix Coronary Plaque use at Tanner Health after introducing a pre-authorisation workflow, with elevated activity continuing into October, while it will conduct an additional reader study before filing for FDA clearance of Salix Coronary Flow, later than previously expected. Artrya reported pro forma cash of about $67 million at quarter-end, with an additional research and development rebate claim of about $5 million in process.